Lapatinib is ineffective for breast cancer

Lapatinib, in combination with other cancer drugs, has been shown to improve survival in patients with breast cancer that produces large amounts of HER2, and its side effects are considered acceptable. Different patients may have different responses to drugs, including drug absorption, distribution, metabolism and excretion. These factors may affect the concentration and efficacy of lapatinib in patients. Long-term use of lapatinib may cause tumor cells to become resistant to it, making the drug's therapeutic effect weakened or ineffective. The development of drug resistance may be related to variations in the HER2 signaling pathway, abnormal activation of other related signaling pathways, as well as factors such as drug metabolism and drug transport.